Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of varying degrees of severity with onset or first recognition during pregnancy.1 Approximately, 7% of all pregnancies (the prevalence ranges 1% to 14% depending on ethnicity) are complicated with GDM.2 GDM is associated with increased fetal and maternal morbidity; therefore, a correct diagnosis is important,1 but overdiagnosis increases medical costs and maternal anxiety.3 There are controversies about diagnostic tests and criteria for GDM.5,6 Since the oral glucose tolerance test (OGTT) is time consuming, expensive, and inconvenient, easier tests with the same diagnostic value have been studied.7-11

The relationship between markedly elevated glucose challenge test results and the rate of gestational diabetes mellitus and gestational impaired glucose tolerance

Deniz Karcaaltincaba,a Sadiman Altinbas,a Mesut Akyol,b Tugba Ensari,a Serdar Yalvaça

From the aDepartment of Obstetrics and Gynecology, Ankara Etlik Zubeyde Hanım Maternity and Women’s Health Teaching and Research Hospital, Ankara, bDepartment of Biostatistics, Gülhane Military Medical Academy, Ankara, Turkey

Correspondence: Deniz Karcaaltincaba, MD · Department of Obstetrics and Gynecology, Etlik Zubeyde Hanım Women’s Hospital, Ankara, Turkey · T: +90 505 2363960, F: +90 312 3112145 · denizaltincaba@yahoo.com

Ann Saudi Med 2012; 32(4): 391-396
DOI: 10.5144/0256-4947.2012.391

BACKGROUND AND OBJECTIVES: Even though the 50 g oral glucose challenge test (GCT) is the most commonly used screening modality for gestational diabetes mellitus (GDM), no consensus for the diagnostic approach is available to patients with a markedly elevated GCT result. We aimed to evaluate the diagnostic utility of markedly elevated GCT results and the impact of age using the oral glucose tolerance test (OGTT) as gold standard.

DESIGN AND SETTING: Retrospective study conducted in a women’s hospital in Ankara, among patients who underwent GCT from January 2005 to December 2008.

PATIENTS AND METHODS: In this retrospective study, we included 626 pregnant women who underwent a 3-hour 100 g OGTT after a GCT result ≥180 mg/dL among 29842 women. We calculated positive predictive values (PPV) of each GCT category to diagnose GDM and both GDM and gestational impaired glucose tolerance (GIGT).

RESULTS: A GCT result of ≥240 mg/dL provided 100% PPV for the diagnosis of GDM and a result of >230 mg/dL provided 100% PPV for the diagnosis of GDM + gestational impaired glucose tolerance (GIGT), according to both, National Diabetes Data Group (NDDG) and Carpenter and Coustan (CC) criteria. A result of ≥200 mg/dL provided 100% PPV for diagnosing GDM+GIGT in patients older than 35 years, according to the CC criteria.

CONCLUSIONS: The GCT result of 200 mg/dL is an ideal cutoff value for the diagnosis of GDM + GIGT in patients ≥35 years, and OGTT can be omitted in these patients. In younger patients, the cutoff value should be chosen as 230 mg/dL.
ed diagnosing GDM if the glucose level 1 hour after the GCT is 190 mg/dL. However, the American Congress of Obstetricians and Gynecologists (ACOG) guidelines for GDM advised GCT only for screening purposes and did not define any threshold. Even though there is a lack of consensus in patients with markedly elevated screening results, there is a tendency to diagnose GDM, especially, with GCT results ≥200 mg/dL. Our aim in this study was to evaluate the association between markedly elevated (≥180 mg/dL) GCT results and OGTT for the diagnosis of GDM and gestational impaired glucose tolerance (GIGT) according to both National Diabetes Data Group (NDDG) and CC criteria and whether this association differs in different age groups.

PATIENTS AND METHODS
This retrospective study was approved by the ethics committee of our hospital. We retrieved the records of patients who underwent a GCT between the years 2005 and 2008 from the hospital information system. We found 29,842 women who fulfilled the criteria. Among these women, 626 women with a GCT result ≥180 mg/dL underwent OGTT. These patients comprised the study group. We screened for GDM in all nondiabetic pregnancies using a 2-step standard protocol. At 24 to 28 weeks, all pregnant women without previously diagnosed diabetes were offered screening for GDM with a 1-h 50 g GCT during a routine prenatal visit, regardless of the time of the fasting. In this study, all the patients underwent both GCT and OGTT. The results of GCT and OGTT were not influenced by each other.

We reviewed the results according to both NDDG (8 patients) (plasma glucose thresholds: fasting 105 mg/dL, 1-h 190 mg/dL, 2-h 165 mg/dL, 3-h 145 mg/dL) and CC criteria (8 patients) (plasma glucose thresholds: fasting 95 mg/dL, 1-h 180 mg/dL, 2-h 155 mg/dL, 3-h 140 mg/dL). By both criteria, GDM is defined as at least two plasma glucose measurements at or higher than the reported cutoff values. GIGT is defined as a 1 plasma glucose measurement at or higher than the reported cutoff values during the diagnostic test.

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) (SPSS Inc, Chicago, IL, USA) version 10. Receiver-operator characteristic (ROC) curves were generated and areas under the curve (AUC) were calculated for each data set of GDM, and both GDM and GIGT were diagnosed by NDDG and CC criteria. The significance of AUCs were controlled with Bonferroni Corrections (type I error rate=0.05/4=0.0125). For the purpose of analysis, screening test results were categorized by 10 mg/dL increments. We investigated positive predictive values (PPV) of each GCT category to diagnose GDM and GDM + GIGT, according to the NDDG and CC criteria. The cutoff points were computed if all the patients were diagnosed as GDM and GDM + GIGT (100% PPV) in a given 50 g GCT results. We further investigated cutoff points of GCT results in patients ≥35 years of age.

RESULTS
The mean (standard deviation) age of subjects were 31.4 (5.9); 11% (n=69) were less than 25 years old, 59.6% (n=373) were 25 to 34 years, and 29.4% (n=184) were equal to or more than 35 years old. Thirty-four percent subjects (n=213) had GDM, 53% (n=332) had GDM + GIGT by NDDG criteria, and 48.1% (n=301) had GDM, and 73.3% (n=396) had GDM + GIGT by CC criteria. The diagnosis of GDM was confirmed in only 25.4% of patients according to the NDDG criteria and 37.7% according to the CC criteria with GCT results between 180 and 189 mg/dL, and 39.5% of patients according to the NDDG criteria and 60.5% according to the CC criteria with GCT results between 200 and 209 mg/dL. A GCT result of ≥240 mg/dL provided 100% PPV for the diagnosis of GDM according to both criteria and was chosen as cutoff points (Table 1). For GDM and GIGT together, the diagnosis was confirmed in 40.7% of the patients according to the NDDG criteria, 50.8% according to the CC criteria with GCT results between 180 and 189 mg/dL, 65.4% according to the NDDG criteria, and 74.1% according to the CC criteria with GCT results between 200 and 209 mg/dL. A GCT result of ≥230 mg/dL provided 100% PPV for the diagnosis of GDM + GIGT according to both criteria (Table 1).

The AUC calculated by the ROC curve analysis of GCT results ≥180 mg/dL for diagnosing GDM and GDM + GIGT using NDDG and CC criteria are given in Table 2. The AUC for GDM using the NDDG and CC criteria were 0.653 and 0.658, which are statistically significant (P<.0001 and P<.0001, respectively). The AUC for GDM + GIGT using NDDG and CC criteria were 0.674 and 0.680, which are statistically significant (P<.0001 and P<.0001, respectively). ROC curves of each analysis are given in Figure 1.

In patients ≥35 years, a GCT result of ≥220 mg/dL provided 100% PPV for the diagnosis of GDM according to both criteria, and for the diagnosis of GDM + GIGT according to the NDDG criteria. A result of ≥200 mg/dL provided 100% PPV for diagnosing GDM + GIGT in patients older than 35 years according to the CC criteria and was chosen as the cutoff point (Table 3). The AUC calculated by the ROC
Table 1. Rate of GDM and GDM + GIGT diagnosed according to GCT results using NDDG criteria and Carpenter and Coustan criteria in all ages.

| GCT | National Diabetes Data Group | GDM | GDM + GIGT | Total | Total | Total |
|-----|-----------------------------|-----|------------|-------|-------|-------|
| ≥240 | 6 (100%) | 0 | GCT | ≥230 | 10 (100%) | 0 | 10 |
| <240 | 207 (33.4%) | 413 (66.6%) | 620 | <230 | 322 (52.4%) | 294 (47.6%) | 616 |
| Total | 213 (34%) | 413 (66%) | 626 | Total | 332 (53%) | 294 (47%) | 626 |

| GCT | Carpenter and Coustan criteria | GDM | GDM + GIGT | Total | Total | Total |
|-----|--------------------------------|-----|------------|-------|-------|-------|
| ≥240 | 6 (100%) | 0 | GCT | ≥230 | 10 (100%) | 0 | 10 |
| <240 | 207 (33.4%) | 413 (66.6%) | 620 | <230 | 322 (52.4%) | 294 (47.6%) | 616 |
| Total | 213 (34%) | 413 (66%) | 626 | Total | 332 (53%) | 294 (47%) | 626 |

GDM: Gestational diabetes mellitus; GIGT: Gestational impaired glucose intolerance; GCT: Glucose challenge test.

Table 2. Receiver-operator characteristic curve analysis of GCT results ≥180 mg/dL for diagnosing GDM and GDM + GIGT using NDDG and CC criteria in all patients.

| Criteria | Diagnosis | AUC | 95% CI | P |
|----------|-----------|-----|--------|----|
| NDDG     | GDM       | 0.653 | 0.604-0.703 | <.0001 |
|          | GDM + GIGT | 0.674 | 0.627-0.716 | <.0001 |
| CC       | GDM       | 0.658 | 0.613-0.703 | <.0001 |
|          | GDM + GIGT | 0.680 | 0.635-0.725 | <.0001 |

Table 2. Receiver-operator characteristic curve analysis of GCT results ≥180 mg/dL for diagnosing GDM and GDM + GIGT using NDDG and CC criteria in all patients.

DISCUSSION
OGTT is designed on the basis that the diabetogenic stress of pregnancy is best recognized in the fed state. OGGT has become established as the gold standard diagnostic test for gestational diabetes. However, it is time consuming, expensive, and unpleasant; therefore, new and easy diagnostic tests need to be validated against OGTT.

Two main criteria, NDDG and CC, are commonly used to examine 3-h OGTT. In 1964, O’Sullivan and Mahan for the first time suggested that pregnancy glucose values obtained during a 100 g 3-h OGTT should be used to diagnose GDM. In 1979, the NDDG recommended new diagnostic thresholds, and most laboratories changed from using venous whole blood samples to using plasma or serum samples.1 In 2000, the American Diabetes Association (ADA) revised the recommendation for the GDM diagnostic criteria and proposed adoption of CC thresholds, which represented the most accurate conversion of the O’Sullivan and Mahan criteria, rather than the NDDG thresholds, to reduce the risks of adverse perinatal outcomes attributable to GDM.15 The prevalence rates of GDM have been increased by using CC criteria.16,17 ACOG and ADA currently recommend the use of CC criteria.2,3

In this study, we investigated the PPV of GCT results ≥180 mg/dL for diagnosing GDM and both GDM and GIGT according to the NDDG and CC criteria in Turkish pregnant women. The PPV of GCT result between 180 to 189 mg/dL was only 25.4% according to the NDDG diagnostic criteria, and 37.7% according to the CC diagnostic criteria. When we considered the predictive value of GCT for diagnosing both GDM and GIGT, we reached 100% PPV at the GCT level of 230 mg/dL and greater according to both criteria. When we considered the predictive value of GCT for diagnosing both GDM and GIGT, we reached 100% PPV at the GCT level of 230 mg/dL and greater according to both criteria.

Several studies have been performed in establishing...
the diagnostic value of markedly elevated GCT levels for gestational diabetes.\textsuperscript{7-11} Lanni and Barrett reported that a cutoff value 200 mg/dL predicted only 47\% to 54\% of GDM cases, so it was inappropriate for GDM to be diagnosed based on the GCT, and this might lead to overdiagnosis.\textsuperscript{13} Cheng et al reported 100\% PPV for GCT results $\geq 230$ mg/dL for diagnosing GDM according to the CC criteria, which was similar to our findings.\textsuperscript{11}

The prevalence of GDM differs depending on the population being screened. In studies conducted in North America, the prevalence was higher in Asian, African American, Native American, and Hispanic compared to non-Hispanic white patients.\textsuperscript{16} Because of variations in the prevalence based on ethnicity, it has been suggested that race-specific glucose screening test thresholds should be used.\textsuperscript{18} Esakoff et al reported different sensitivity and specificity results for GCT in different ethnic groups.\textsuperscript{19} Dooley et al defined a 90\% risk of GDM with GCT result $\geq 200$ mg/dL in nonwhite women, but the risk in white women was 66\%.\textsuperscript{9} Based on these findings, it is logical that different cutoff levels may be accepted in different ethnic groups for diagnosing GDM without performing further OGGT. One of the studies conducted in Turkey reached 100\% specificity after a cutoff value of 221 mg/dL, which was lower compared to our findings.\textsuperscript{20} Besides ethnicity, one of the major risk factors for GDM is increased maternal age.\textsuperscript{16,17} Therefore, we investigated whether the PPV of GCT levels for GDM diagnosis differ in different age groups and we further analyzed our results according to age. After analyzing patients older than 35 years, we reached 100\% PPV at the GCT level of 200 mg/dL or greater for diagnosing both GDM and GIGT according to the CC criteria. Our results showed that 100\% PPV can be reached with lower GCT results in patients older than 35 years.

An important limitation regarding GCT results is low reproducibility. Only 83\% of abnormal results were reproducible the next day in a study by Espinosa de los Monteros et al.\textsuperscript{21} This was attributed to the fact that the reproducibility of the test would rely on the timing since the last meal. In pregnancy, plasma glucose concentrations after GCT were higher if administered in the fasting state compared with the postprandial state, and this effect might alter the test characteristics.\textsuperscript{22} Therefore, it is important to be cautious in using GCT for diagnostic purposes.

Accuracy is measured by the area under the ROC curve, which summarizes the discriminative ability of a test and provides a measure of the overall performance of a diagnostic test. The greater the value of AUC, the
Table 3. Rate of GDM and GDM + GIGT diagnosed according to GCT results using NDDG criteria and Carpenter and Coustan criteria in patients ≥35 years.

|                   | National Diabetes Data Group | GDM+GIGT |
|-------------------|-----------------------------|----------|
|                   | +  | -  | Total | +  | -  | Total |
| GCT               |    |    |       |    |    |       |
| ≥220              | 12 (100%) | 0 | 12 | 12 (100%) | 0 | 12 |
| <220              | 73 (42.3%) | 99 (57.7%) | 172 | 111 (64.5%) | 61 (35.5%) | 172 |
| Total             | 85 (46.1%) | 99 (53.9%) | 184 | 123 (66.8%) | 61 (33.2%) | 184 |

|                   | Carpenter and Coustan criteria | GDM | GDM+GIGT |
|-------------------|--------------------------------|-----|----------|
|                   | +  | -  | Total | +  | -  | Total |
| GCT               |    |    |       |    |    |       |
| ≥220              | 12 (100%) | 0 | 12 | 32 (100%) | 0 | 32 |
| <220              | 94 (54.6%) | 82 (45.4%) | 172 | 128 (84.2%) | 24 (15.8) | 152 |
| Total             | 106 (57.2%) | 82 (42.8%) | 184 | 160 (87.8%) | 24 (12.2%) | 184 |

GDM: Gestational diabetes mellitus; GIGT: Gestational impaired glucose intolerance.

Table 4. Receiver-operator characteristic curve analysis of GCT results ≥180 mg/dL for diagnosing GDM and GDM + GIGT using NDDG and CC criteria in patients ≥35 years.

| Criteria | Diagnosis    | AUC  | 95% CI           | P value |
|----------|--------------|------|------------------|---------|
| NDDG     | GDM          | 0.599| 0.509-0.690      | .0293*  |
|          | GDM + GIGT   | 0.629| 0.544-0.713      | .0070   |
| CC       | GDM          | 0.597| 0.511-0.684      | .0331*  |
|          | GDM + GIGT   | 0.630| 0.542-0.718      | .0127   |

GCT: Glucose challenge test; GDM: gestational diabetes mellitus; GIGT: gestational impaired glucose intolerance; NDDG: National Diabetes Data Group; CC: Carpenter and Coustan; AUC: area under curve; CI: confidence interval.

Better would be the test. In this study, for GCT values ≥180 mg/dL, we generated ROC curves and calculated AUC. The best value was 0.680 in the curve of GDM + GIGT diagnoses using CC criteria, which provided low accuracy. This is the first study analyzing PPVs of GCT results for diagnosing both GDM and GIGT. Although, women with one elevated glucose tolerance test value are not diagnosed with GDM, they may still be at risk of adverse perinatal outcomes, and dietary counseling and glucose monitoring is recommended to decrease perinatal morbidity. Women with one elevated glucose tolerance test value have an increased likelihood of developing an abnormal glucose tolerance later in life, which is similar to the risk in women with gestational diabetes. Since most clinicians offer glucose monitoring for GIGT, we analyzed the predictive value of GCT results for diagnosing GDM and both GDM and GIGT.

The major limitation of our study is its retrospective design, but it would be difficult to include a large cohort in a prospective study. We could not analyze the effect of other risk factors like maternal weight, positive family history of diabetes, and personal history of previous gestation diabetes. Also, we did not assess the reproducibility of GCT results and obstetric outcomes. However, we focused on the impact of age for the diagnostic utility of GCT results for diagnosing GDM and GIGT. Our data suggest that we may omit OGTT in pregnant women with GCT results ≥230 mg/dL. A cutoff value of 200 mg/dL can be used in patients older than 35 years. This approach may prevent overdiagnosis, and unnecessary interventions can be avoided.
REFERENCES

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
2. ADA Position Statement: Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2007;30(Suppl 1):142-7.
3. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol 2001;98:525-38.
4. Brody SC, Harris R, Lohr K. Screening for gestational diabetes: A summary of the evidence for the U.S. Preventive Services Task Force. Obstet Gynecol 2002;101:380-92.
5. Hanna FW, Peters JR. Screening for gestational diabetes; past, present and future. Diabet Med 2002;19:351-8.
6. Reece EA, Leguizamón G, Wiznitzer A. Gestational diabetes: The need for a common ground. Lancet 2003;361:1769-77.
7. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982;144:768-73.
8. Bobrovski RA, Bottoms SF, Micallef JA, Domrowski MP. Is the 50-gram glucose screening test ever diagnostic? J Matern Fetal Med 1996;5:317-20.
9. Dooley SL, Metzger BE, Cho N, Liu K. The influence of demographic and phenotypic heterogeneity on the prevalence of gestational diabetes mellitus. Int J Gynaecol Obstet 1991;35:13-8.
10. Lanni S, Barrett D. The predictive value of the 1-h 50-g glucose screen for diagnosing gestational diabetes mellitus in a high-risk population. J Matern Fetal Neonatal Med 2004;15:375-9.
11. Cheng YW, Esakoff TF, Block-Kurbisch I, Ustunov A, Shafer S, Caughhey AB. Screening or diagnostic: Markedly elevated glucose loading test and perinatal outcomes. J Matern Fetal Neonatal Med 2006;19:729-34.
12. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):99-105.
13. Moore TR. Diabetes in pregnancy. In: Creasy R, Resnick R, editors. Maternal Fetal Medicine. 5th ed. Philadelphia, PA: WB Saunders Company; 2004. p. 1023-62.
14. O’Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 1964;13:278-85.
15. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2000;23(Suppl 1):S77-9.
16. Ferrara A, Hederson MM, Quesenberry CP, Selby JV. Prevalence of gestational diabetes mellitus detected by the national diabetes data group or the Carpenter and Coustan plasma glucose thresholds. Diabetes Care 2002;25:1625-30.
17. Karacaaltincaba D, Kandemir O, Yalvac S, Guvendag-Guvn S, Haberal A. Prevalence of gestational diabetes mellitus and gestational impaired glucose tolerance in pregnant women evaluated by National Diabetes Data Group and Carpenter and Coustan criteria. Int J Gynaecol Obstet 2005;90:246-9.
18. Nahum GG, Huffaker BJ. Racial differences in oral glucose screening test results: Establishing race-specific criteria for abnormality in pregnancy. Obstet Gynecol 1993;82:478-80.
19. Esakoff TF, Cheng YW, Caughhey AB. Screening for gestational diabetes: Different cut-offs for different ethnicities? Am J Obstet Gynecol 2005;193:1040-4.
20. Karucugol U, Biri A, Turkyilmaz E, Doga Yildirim F, Ilhan M, Hirfanoglu FM, et al. Glycemic levels with glucose loading test during pregnancy and its association with maternal and perinatal outcomes. Diabetes Res Clin Pract 2008;80:69-74.
21. Espinosa de los Monteros A, Parra A, Carino N, Ramirez A. The reproducibility of the 50-g 1-hour glucose screen for diabetes in pregnancy. Obstet Gynecol 1993;82:515-58.
22. Lewis GF, McNally C, Blackman JD, Polonsky KS, Barron WM. Prior feeding alters the response to the 50-g glucose challenge test in pregnancy. The Staub-Traugott effect revisited. Diabetes Care 1993;16:1551-6.
23. Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr 2007;96:644-7.
24. McLoughlin GB, Cheng YW, Caughhey AB. Women with one elevated 3-hour glucose tolerance test value: Are they at risk for adverse perinatal outcomes? Am J Obstet Gynecol 2006;194:18-9.
25. Corrado F, D’Anna R, Cannata ML, Cannizzaro D, Caputo F, Raffone E, et al. Positive association between a single abnormal glucose tolerance test value in pregnancy and subsequent abnormal glucose tolerance. Am J Obstet Gynecol 2007;196:339.e1-5.